العربية
中国
Français
Deutsch
Ελληνική
हिन्दी
Italiano
日本語
Português
Русский
EspañolSHIRE PHARMACEUTICALS GROUP
(Redirected from Shire Pharmaceuticals)
'Shire plc' () is a British manufacturer of pharmaceuticals including Adderall XR, Carbatrol, and Fosrenol. It was founded in 1986.
Shire’s strategic goal is to become the leading specialty biopharmaceutical company, focusing on meeting the needs of specialist physicians. Shire believes that a carefully selected portfolio of products with a strategically aligned and relatively small-scale sales force will deliver strong results. To this end, Shire focuses its business on medications in the areas of Attention Deficit Hyperactivity Disorder (ADHD), gastrointestinal (GI), renal diseases and human genetic therapies (HGT). The structure is sufficiently flexible to allow Shire to target new therapeutic areas to the extent opportunities arise through acquisitions. Shire believes that a carefully selected portfolio of products with a strategically aligned and relatively small-scale sales force will deliver strong results.
Shire’s focused strategy is to develop and market products for specialty physicians. Shire’s in-licensing, merger and acquisition efforts are focused on products in niche markets with strong intellectual property protection either in the US or Europe.
Shire announced the acquisition of New River Pharmaceuticals on 20th February 2007.
Matthew Emmens is the Chief Executive Officer and Chairman of the Executive Committee. The non-executive Board Chairman is Dr. James Cavanaugh.
★ Adderall XR: Attention Deficit Hyperactivity Disorder
★ Carbatrol: Epilepsy
★ Lialda: Ulcerative Colitis
★ Daytrana: Attention Deficit Hyperactivity Disorder
★ Equetro: Bipolar I Mood Disorder
★ Fosrenol: Hyperphosphatemia associated with End-Stage Renal Disease
★ Pentasa: Ulcerative Colitis
★ Reminyl (also sold as Razadyne): Alzheimer's Disease
★ VYVANSE: Attention Deficit Hyperactivity Disorder
★ Xagrid (sold as Agrylin in the U.S.): Essential Thrombocytosis
★ Replagal: Fabry disease
★ Elaprase: Hunter syndrome
★ Lialda: Ulcerative Colitis
Shire is traded on three stock exchanges:
# The London Stock Exchange, where its symbol is ''SHP.L''. Shire is a constituent of the FTSE 100 Index.
# The NASDAQ, where its symbol is ''SHPGY''.
# The Toronto Stock Exchange, where its symbol is ''SHQ.TO''.
Shire's financial reports can be found at http://www.shire.com/shire/InvestorRelations/reports.jsp?tn=2&m1=22.
The corporate offices are located in Basingstoke, Hampshire. The address is:
:Hampshire International Business Park
:Chineham Basingstoke
:Hampshire
:RG24 8EP
:United Kingdom
Other major offices are located in the United States in Wayne, Pennsylvania and Cambridge, Massachusetts. Plus, Shire owns a manufacturing site in Owings Mills, Maryland.
★ Official site
★ German pharmaceutical branch
★ Yahoo profile
'Shire plc' () is a British manufacturer of pharmaceuticals including Adderall XR, Carbatrol, and Fosrenol. It was founded in 1986.
| Contents |
| Corporate strategy |
| Corporate leadership |
| Key marketed products and indications |
| Financial information |
| Locations |
| External links |
Corporate strategy
Shire’s strategic goal is to become the leading specialty biopharmaceutical company, focusing on meeting the needs of specialist physicians. Shire believes that a carefully selected portfolio of products with a strategically aligned and relatively small-scale sales force will deliver strong results. To this end, Shire focuses its business on medications in the areas of Attention Deficit Hyperactivity Disorder (ADHD), gastrointestinal (GI), renal diseases and human genetic therapies (HGT). The structure is sufficiently flexible to allow Shire to target new therapeutic areas to the extent opportunities arise through acquisitions. Shire believes that a carefully selected portfolio of products with a strategically aligned and relatively small-scale sales force will deliver strong results.
Shire’s focused strategy is to develop and market products for specialty physicians. Shire’s in-licensing, merger and acquisition efforts are focused on products in niche markets with strong intellectual property protection either in the US or Europe.
Shire announced the acquisition of New River Pharmaceuticals on 20th February 2007.
Corporate leadership
Matthew Emmens is the Chief Executive Officer and Chairman of the Executive Committee. The non-executive Board Chairman is Dr. James Cavanaugh.
Key marketed products and indications
★ Adderall XR: Attention Deficit Hyperactivity Disorder
★ Carbatrol: Epilepsy
★ Lialda: Ulcerative Colitis
★ Daytrana: Attention Deficit Hyperactivity Disorder
★ Equetro: Bipolar I Mood Disorder
★ Fosrenol: Hyperphosphatemia associated with End-Stage Renal Disease
★ Pentasa: Ulcerative Colitis
★ Reminyl (also sold as Razadyne): Alzheimer's Disease
★ VYVANSE: Attention Deficit Hyperactivity Disorder
★ Xagrid (sold as Agrylin in the U.S.): Essential Thrombocytosis
★ Replagal: Fabry disease
★ Elaprase: Hunter syndrome
★ Lialda: Ulcerative Colitis
Financial information
Shire is traded on three stock exchanges:
# The London Stock Exchange, where its symbol is ''SHP.L''. Shire is a constituent of the FTSE 100 Index.
# The NASDAQ, where its symbol is ''SHPGY''.
# The Toronto Stock Exchange, where its symbol is ''SHQ.TO''.
Shire's financial reports can be found at http://www.shire.com/shire/InvestorRelations/reports.jsp?tn=2&m1=22.
Locations
The corporate offices are located in Basingstoke, Hampshire. The address is:
:Hampshire International Business Park
:Chineham Basingstoke
:Hampshire
:RG24 8EP
:United Kingdom
Other major offices are located in the United States in Wayne, Pennsylvania and Cambridge, Massachusetts. Plus, Shire owns a manufacturing site in Owings Mills, Maryland.
External links
★ Official site
★ German pharmaceutical branch
★ Yahoo profile
This article provided by Wikipedia. To edit the contents of this article, click here for original source.
psst.. try this: add to faves
